Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Eur Urol. 2013 Dec;64(6):931-8. doi: 10.1016/j.eururo.2013.02.001. Epub 2013 Feb 14.
Treatment-related toxicity and quality of life (QoL) considerations are important when counseling patients with localized prostate cancer (PCa).
To determine the incidence and longitudinal pattern of late genitourinary (GU) toxicity and QoL after high-dose, intensity-modulated radiotherapy (IMRT).
DESIGN, SETTING, AND PARTICIPANTS: A total of 268 patients with localized PCa were treated between June 2004 and December 2008 at a tertiary referral center. Median follow-up was 5 yr (range: 3-7.7 yr).
Patients underwent IMRT to a total dose of 86.4Gy; 50% of patients underwent neoadjuvant and concurrent androgen-deprivation therapy.
Patients were evaluated with the prospectively obtained International Prostate Symptom Score (IPSS) questionnaire. GU toxicity was also scored using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0; toxicity events were defined as increase over baseline. Differences in increases in IPSS sums and QoL index between baseline IPSS sum and QoL index groups were analyzed using the Kruskal-Wallis and Mann-Whitney tests. Univariate and multivariate Cox regression models were applied.
The overall median IPSS sum increase during follow-up was 3 and was less pronounced among patients with severe baseline symptoms compared with those with mild baseline symptoms (median increase: 0 vs 4; p<0.0001). Overall QoL index was unchanged after IMRT but appeared to improve in patients with dissatisfied baseline QoL compared with satisfied baseline QoL (p<0.0001). Fifty-five (20%) and 2 (1%) patients developed grade 2 and 3 late GU toxicities, respectively; however, in 28 of 57 patients (49%), toxicity resolved during follow-up. Even though the IPSS data were prospectively obtained, most patients were not treated within a prospective protocol.
Late GU toxicity after high-dose IMRT was mild; severe, late GU toxicity was rare. Changes in IPSS sum and QoL index were dependent on the baseline GU function, which might be useful for future patient counseling.
在为局限性前列腺癌(PCa)患者提供咨询时,需要考虑与治疗相关的毒性和生活质量(QoL)。
确定高强度调强放疗(IMRT)后晚期泌尿生殖系统(GU)毒性和 QoL 的发生和纵向模式。
设计、地点和参与者:共 268 例局限性 PCa 患者于 2004 年 6 月至 2008 年 12 月在一家三级转诊中心接受治疗。中位随访时间为 5 年(范围:3-7.7 年)。
患者接受 86.4Gy 的 IMRT 总剂量;50%的患者接受新辅助和同步雄激素剥夺治疗。
患者采用前瞻性获得的国际前列腺症状评分(IPSS)问卷进行评估。GU 毒性也采用不良事件常用术语标准(CTCAE)v.4.0 进行评分;毒性事件定义为较基线增加。采用 Kruskal-Wallis 和 Mann-Whitney 检验分析基线 IPSS 总和 QoL 指数组之间 IPSS 总和和 QoL 指数增加的差异。应用单变量和多变量 Cox 回归模型。
随访期间总体中位 IPSS 总和增加 3 分,基线症状严重的患者增加幅度小于基线症状轻微的患者(中位增加:0 分与 4 分;p<0.0001)。IMRT 后总体 QoL 指数保持不变,但与基线 QoL 满意度相比,基线 QoL 不满意的患者似乎有所改善(p<0.0001)。55 例(20%)和 2 例(1%)患者分别发生 2 级和 3 级晚期 GU 毒性,但在 57 例患者中有 28 例(49%)毒性在随访期间得到缓解。尽管 IPSS 数据是前瞻性获得的,但大多数患者并未按前瞻性方案进行治疗。
高剂量 IMRT 后晚期 GU 毒性较轻;严重的晚期 GU 毒性罕见。IPSS 总和和 QoL 指数的变化取决于基线 GU 功能,这可能对未来的患者咨询有用。